


THE POWER TO MOVE YOU **ARCOXIA**[®]
(etoricoxib, MSD)

24
שעות¹

של הקלה עוצמתית בכאב ודלקת^{2*}
גם בכאב אקוטי
מחקר חדש מדגים את יעילות
ARCOXIA במודל של כאב אקוטי³

"Different acute pain models exist for the evaluation of analgesic treatments with the **postoperative dental pain model being among the most common** and well standardized.³"

ARCOXIA 87% מהמטופלים דרגו את היעילות של
טובה עד מצויינת!³



על מנת להגיע ליעילות של כדור אחד ביממה של ארקוקסיה 90 מ"ג,
החולים נזקקו ל-4 מנות ביממה של איבופרופן 600 מ"ג

Patient Global Assessment of Study Medication

Adapted from Daniels et. al³ ** Ibuprofen 600mg 4 times daily *** Acetaminophen (Paracetamol) / Codeine 600/60mg 4 times daily



THE POWER TO MOVE YOU **ARCOXIA**[®]
(etoricoxib, MSD)

של הקלה עוצמתית בכאב ודלקת^{2*}

24
שעות¹

עכשיו
ב-38 שקלים
בביטוחים המשלימים
של כל קופות
החולים



Therapeutic Indications¹:

For the symptomatic relief of osteoarthritis (OA) (30 mg and 60 mg), rheumatoid arthritis (RA) (90 mg), ankylosing spondylitis (90 mg), and the pain and signs of inflammation associated with acute gouty arthritis (120 mg).

For the short-term treatment of moderate pain associated with dental surgery (90 mg).

Contraindications

- Hypersensitivity to the active substance or to any of the excipients.
- Active peptic ulceration or active gastro-intestinal (GI) bleeding.
- Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
- Pregnancy and lactation.
- Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10)
- Estimated renal creatinine clearance <30 ml/min.
- Children and adolescents under 16 years of age.
- Inflammatory bowel disease.
- Congestive heart failure (NYHA II-IV)
- Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled.
- Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.

For special warnings, precautions for use and common/ clinically significant adverse events, please refer to the Physicians information leaflet

לפי מתן מרשם יש לעיין בעלון לרופא כפי שאושר על ידי משרד הבריאות

*למצבים המופיעים בהתוויה

References:

1. עלון לרופא כפי שאושר על ידי משרד הבריאות בישראל.
 2. Matsumoto AK, Melian A, Mandel DR, et al; for Etoricoxib Rheumatoid Arthritis Study Group. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29(8): 1623-1630.
 3. Daniels SE et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain. 2011;27(1):1-8.
- Study design: A randomized, double-blind, placebo-controlled, and active comparator-controlled, parallel-group study carried out under inhouse blinding conditions to compare the analgesic effect of etoricoxib (90 and 120 mg) with that of placebo, ibuprofen (600 mg), and acetaminophen (600 mg)/codeine (60 mg) (A/C) over the first 6 hours post dose, in 588 patients aged ≥18 years with moderate or severe pain after surgical extraction of ≥2 third molars (≥ impacted). The patients reported pain intensity and pain relief over 24 hours. The primary efficacy endpoint was total pain relief over 6 hours (TOPAR6).



Copyright © Merck Sharp & Dohme (Israel-1996)
Company Ltd., 2012. All rights reserved.
MUSC-1064725-0000